NKGen Biotech (NKGN) Competitors $0.13 -0.01 (-4.72%) As of 05/2/2025 03:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NKGN vs. CYTH, CASI, EGRX, DRRX, SNYR, LGVN, CGTX, PULM, ELEV, and PASGShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Cyclo Therapeutics (CYTH), CASI Pharmaceuticals (CASI), Eagle Pharmaceuticals (EGRX), DURECT (DRRX), Synergy CHC Corp. (Uplisting) (SNYR), Longeveron (LGVN), Cognition Therapeutics (CGTX), Pulmatrix (PULM), Elevation Oncology (ELEV), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Cyclo Therapeutics CASI Pharmaceuticals Eagle Pharmaceuticals DURECT Synergy CHC Corp. (Uplisting) Longeveron Cognition Therapeutics Pulmatrix Elevation Oncology Passage Bio Cyclo Therapeutics (NASDAQ:CYTH) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Does the MarketBeat Community believe in CYTH or NKGN? Cyclo Therapeutics received 10 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformCyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% NKGen BiotechN/AN/A Do analysts recommend CYTH or NKGN? Cyclo Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 31.83%. Given Cyclo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cyclo Therapeutics is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, CYTH or NKGN? Cyclo Therapeutics has a beta of -0.57, meaning that its share price is 157% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Do institutionals and insiders believe in CYTH or NKGN? 68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by company insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, CYTH or NKGN? Cyclo Therapeutics has higher revenue and earnings than NKGen Biotech. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclo Therapeutics$870.73K27.24-$20.06M-$0.90-0.80NKGen Biotech$80K71.41-$82.94M-$2.45-0.05 Is CYTH or NKGN more profitable? NKGen Biotech has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Company Net Margins Return on Equity Return on Assets Cyclo Therapeutics-2,847.19% N/A -307.16% NKGen Biotech N/A N/A -479.36% Does the media prefer CYTH or NKGN? In the previous week, Cyclo Therapeutics had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Cyclo Therapeutics and 0 mentions for NKGen Biotech. Cyclo Therapeutics' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score. Company Overall Sentiment Cyclo Therapeutics Neutral NKGen Biotech Neutral SummaryCyclo Therapeutics beats NKGen Biotech on 10 of the 15 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$5.71M$2.97B$5.55B$19.20BDividend YieldN/A1.87%5.09%4.00%P/E Ratio-0.0330.5222.7133.50Price / Sales71.41494.90405.5829.18Price / CashN/A168.6838.1817.52Price / Book-0.053.216.794.55Net Income-$82.94M-$72.35M$3.22B$1.02B7 Day Performance-6.20%13.44%3.33%2.29%1 Month Performance-18.53%12.29%6.89%2.93%1 Year Performance-91.11%-23.53%16.20%4.67% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen BiotechN/A$0.13-4.7%N/A-90.4%$5.71M$80,000.00-0.03N/ACYTHCyclo Therapeutics1.3766 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809CASICASI Pharmaceuticals3.4316 of 5 stars$1.92-1.0%$4.00+108.3%-27.2%$23.61M$28.54M-0.86180Positive NewsEGRXEagle PharmaceuticalsN/A$1.80+11.1%N/A-55.2%$23.38M$257.55M0.00100Analyst ForecastNews CoverageGap DownDRRXDURECT0.3661 of 5 stars$0.74-1.0%N/A-39.6%$23.15M$2.03M-1.2180SNYRSynergy CHC Corp. (Uplisting)2.6705 of 5 stars$2.68+7.6%$10.00+273.1%N/A$22.97M$34.83M0.0040News CoveragePositive NewsLGVNLongeveron1.8622 of 5 stars$1.52+4.1%$8.67+470.2%-13.8%$22.69M$2.39M-0.2420News CoveragePositive NewsGap UpCGTXCognition Therapeutics3.4882 of 5 stars$0.36-2.4%$7.13+1,859.6%-77.5%$22.53MN/A-0.3720Upcoming EarningsShort Interest ↓News CoveragePULMPulmatrix0.6969 of 5 stars$6.16-2.4%N/A+214.3%$22.48M$7.81M-2.3320Upcoming EarningsShort Interest ↓ELEVElevation Oncology2.6668 of 5 stars$0.38-2.0%$3.39+795.5%-90.8%$22.39MN/A-0.4640Positive NewsPASGPassage Bio1.8599 of 5 stars$0.36+9.1%$7.50+1,983.3%-70.5%$22.37MN/A-0.31130 Related Companies and Tools Related Companies Cyclo Therapeutics Alternatives CASI Pharmaceuticals Alternatives Eagle Pharmaceuticals Alternatives DURECT Alternatives Synergy CHC Corp. (Uplisting) Alternatives Longeveron Alternatives Cognition Therapeutics Alternatives Pulmatrix Alternatives Elevation Oncology Alternatives Passage Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
